Shortage of Fluoxetine 10mg tablets to continue till 21st November


Share post:

The shortage of Fluoxetine 10mg tablets which was expected to end on August 13, has been further extended to November 21, 2021. 

The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Fluoxetine 10mg tablets (SSP05).

SSP05 for Fluoxetine 10mg tablets was previously expected to expire on 17th May 2021 but it was extended to 13th August 2021. Now the SSP05 for Fluoxetine 10mg tablets is further extended till November.

SSP05 provides that 1 x Fluoxetine 10mg capsule may be supplied for every prescribed Fluoxetine 10mg tablet.

The Pharmaceutical Services Negotiating Committee said: “Pharmacists should ensure they are using the latest version of an SSP before considering the supply of an alternative product. Reimbursement is for the medicine supplied in accordance with the SSP and not the originally prescribed medicine. The reimbursement price will account for VAT payment. Supply in accordance with the SSP will result in the following fees being paid to the contractor- One Single Activity fee (currently £1.27) and One SSP fee (£5.35).”


Please enter your comment!
Please enter your name here

Current Issue October 2023

Related articles

England lost more than 1,000 pharmacies in the last eight years, says CCA

Community pharmacies are currently facing a worrying mix of funding, workforce, and workload pressures The Company Chemists’ Association...

NHS care delays led to 112 deaths, harmed 8,000 people in England last year

The number of patients dying due to care delays have risen more than fivefold over the last three...

Whitworth Chemists puts six high-dispensing Blackpool pharmacies up for sale

The family-owned business has decided to sell all 34 pharmacies across the North of England Whitworth Chemists Limited...

Babies born with Wolman disease can now receive a life-saving treatment on the NHS

The new enzyme replacement therapy improves patient’s life expectancy and quality of life in clinical trials   For the first...